| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/02/2008 | EP1937669A1 Novel benzopyran derivatives as potassium channel openers |
| 07/02/2008 | EP1937668A1 Octahydropentalene-substituted pyrazoline derivatives, their preparation and use as medicaments |
| 07/02/2008 | EP1937667A2 Benzimidazoles useful as inhibitors of protein kinases |
| 07/02/2008 | EP1937666A1 Substituted heterocyclic compounds with cxcr3 antagonist activity |
| 07/02/2008 | EP1937665A1 4- (4-BROMO-2-FLUOROANILINO) -6-METHOXY-7- (l-METHYLPIPERIDIN-4 -YLMETHOXY) QUINAZOLINE MONOHYDRATE |
| 07/02/2008 | EP1937663A1 Thiophene derivatives as ppar agonists i |
| 07/02/2008 | EP1937659A1 Cyclic n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals |
| 07/02/2008 | EP1937658A1 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals |
| 07/02/2008 | EP1937657A1 N-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals |
| 07/02/2008 | EP1937656A1 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3h)-one-derivatives as beta 2 adrenoceptor agonists |
| 07/02/2008 | EP1937655A1 Hiv-1 protease inhibitors, and methods of making and using them |
| 07/02/2008 | EP1937653A1 Pyrimidine derivatives and their use as kcnq potassium channels openers |
| 07/02/2008 | EP1937652A1 Pyrimidine amide compounds as pgds inhibitors |
| 07/02/2008 | EP1937651A1 Nnrt inhibitors |
| 07/02/2008 | EP1937650A1 Heterocyclic compounds |
| 07/02/2008 | EP1937649A1 Imidazole derivatives for the treatment of anxiety and related diseases |
| 07/02/2008 | EP1937648A1 Diacyl indazol derivatives as lipase and phospholipase inhibitors |
| 07/02/2008 | EP1937647A1 Condensed pyrazole derivatives as ppar agonists ii |
| 07/02/2008 | EP1937646A1 Tetrahydro-cyclopentyl pyrazole cannabinoid modulators |
| 07/02/2008 | EP1937645A1 Pyrazoles useful in the treatment of inflammation |
| 07/02/2008 | EP1937644A1 Novel ansamycin derivatives |
| 07/02/2008 | EP1937643A2 Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| 07/02/2008 | EP1937641A2 Dihydro-[1h]-quinolin-2-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes |
| 07/02/2008 | EP1937640A2 1,2,3,5-tetrahydro-cyclopental[c]quinolin-4-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes |
| 07/02/2008 | EP1937639A2 Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4) |
| 07/02/2008 | EP1937636A1 Processes for the purification of (3r,4s)-4-(4-hydroxy-protected-phenyl)-1-(4-fluorophenyl)-3-(4-fluorophenyl)-3-oxopropyl¨azetidin-2-one |
| 07/02/2008 | EP1937635A2 Ozonised oil, process for the preparation and use thereof in medical field |
| 07/02/2008 | EP1937634A1 Cathepsin cysteine protease inhibitors |
| 07/02/2008 | EP1937633A1 Biphenyloxyacetic acid derivatives for the treatment of respiratory disease |
| 07/02/2008 | EP1937631A2 Hiv-1 protease inhibitors |
| 07/02/2008 | EP1937622A1 Compounds for treatment of lipase-mediated diseases |
| 07/02/2008 | EP1937619A1 Novel unsaturated fatty hydroxy acid derivatives and the dermocosmetologic use thereof |
| 07/02/2008 | EP1937366A1 Synergistic mixtures of bisabolol and ginger extract |
| 07/02/2008 | EP1937363A2 Use of compounds comprising fatty acid entities |
| 07/02/2008 | EP1937362A2 Bisphosphonate formulation |
| 07/02/2008 | EP1937326A1 Isolation and cultivation of stem/progenitor cells from the amniotic membrane of umbilical cord and uses of cells differentiated therefrom |
| 07/02/2008 | EP1937308A1 Synthetic polyvalent carbohydrates as components of microbicides |
| 07/02/2008 | EP1937303A2 The induction of indoleamine 2,3-dioxygenase in dendritic cells by tlr ligands and uses thereof |
| 07/02/2008 | EP1937288A2 Carotenoid oxidation products as chemopreventive and chemotherapeutic agents |
| 07/02/2008 | EP1937286A2 Compositions comprising dimethyl sulfoxide (dmso) |
| 07/02/2008 | EP1937284A1 Microbicidal dendrimer composition delivery system |
| 07/02/2008 | EP1937283A2 Combination formulations of cytidine analogs and platinum agents |
| 07/02/2008 | EP1937282A1 Chitosan and heparin nanoparticles |
| 07/02/2008 | EP1937281A2 Modulation of trpv expression levels |
| 07/02/2008 | EP1937280A2 Compositions and methods for the diagnosis and therapy of bcl2-associated cancers |
| 07/02/2008 | EP1937279A2 Use of inhibitors of pi3k-c2a for the treatment of apoptosis-related disorders |
| 07/02/2008 | EP1937277A1 Method of acting upon organism by targeted delivery of biologicaly active substances into m itochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose |
| 07/02/2008 | EP1937276A2 Improved testosterone gel and method of use |
| 07/02/2008 | EP1937275A1 Method for preventive hormonal contraception on demand |
| 07/02/2008 | EP1937274A2 Use of estradiol valerate combined with dienogest for oral therapy of dysfunctional uterine bleeding in the form of oral contraceptives |
| 07/02/2008 | EP1937273A1 Method for manufacturing a monophasic pharmaceutical product for oral therapy of dysfunctional uterine bleeding |
| 07/02/2008 | EP1937272A2 Benzodiazepines as hcv inhibitors |
| 07/02/2008 | EP1937271A1 Microangiopathy treatment and prevention |
| 07/02/2008 | EP1937270A1 Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof |
| 07/02/2008 | EP1937269A1 Process for the production of contraceptive formulations |
| 07/02/2008 | EP1937268A2 Indenoisoquinolinone analogs and methods of use thereof |
| 07/02/2008 | EP1937267A2 M3 muscarinic acetylcholine receptor antagonists |
| 07/02/2008 | EP1937266A1 Compositions containing opioid antagonists |
| 07/02/2008 | EP1937265A2 Comination of a hypnotic agent and r(+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenl)ethyl]-4-piperidinemethanol and therapeutic application thereof |
| 07/02/2008 | EP1937264A2 Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence |
| 07/02/2008 | EP1937263A2 Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease |
| 07/02/2008 | EP1937262A2 Composition and methods for stimulating gastrointestinal motility |
| 07/02/2008 | EP1937261A1 Novel azabicyclo[3.2.1]oct-2-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 07/02/2008 | EP1937260A2 In-vivo and in-vitro method for detecting amyloid deposits having at least one amyloidogenic protein |
| 07/02/2008 | EP1937259A1 Hexahydro-cycloheptapyrazole cannabinoid modulators |
| 07/02/2008 | EP1937258A2 Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors |
| 07/02/2008 | EP1937257A1 Novel antibiotics comprising bis(1-aryl-5-tetraz0lyl)methane derivatives |
| 07/02/2008 | EP1937256A2 Antiviral therapy with carbohydrate binding agents |
| 07/02/2008 | EP1937255A2 Pharmaceutical composition |
| 07/02/2008 | EP1937254A2 Inhibition of the renin-angiotensin system for the treatment of renal, vascular and cartilage pathology |
| 07/02/2008 | EP1937253A2 Combined preparation of o-acetylsalicylic acid salts |
| 07/02/2008 | EP1937252A2 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration |
| 07/02/2008 | EP1937251A2 Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor |
| 07/02/2008 | EP1937250A2 Ligustilide derivatives for the treatment of inflammatory disorders |
| 07/02/2008 | EP1937249A2 Use of at least one 2-alkyl furan, as depigmenting or lightening active principle |
| 07/02/2008 | EP1937248A2 Alcanoic acid amides substituted by saturated o-heterocycles |
| 07/02/2008 | EP1937247A2 Systemic and intrathecal effects of a novel series of phospholipase a2 inhibitors on hyperalgesia and spinal pge2 release |
| 07/02/2008 | EP1937246A2 Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites |
| 07/02/2008 | EP1937245A1 Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients |
| 07/02/2008 | EP1937244A2 Treatment of cancer with specific rxr agonists |
| 07/02/2008 | EP1937243A2 Naphthyl derivatives as inhibitors of beta-amyloid aggregation |
| 07/02/2008 | EP1937242A2 Methods and compositions for the treatment of neuropsychiatric and addictive disorders |
| 07/02/2008 | EP1937241A1 Pharmaceutical composition for prevention and treatment of drug or alcohol addiction or bipolar disorder using sodium phenylbutyrate |
| 07/02/2008 | EP1937240A2 Compositions for treatment of eye diseases |
| 07/02/2008 | EP1937239A2 Pharmaceutical compositions comprising carboxyalkylsulfonic acids |
| 07/02/2008 | EP1937238A1 Novel nitrocatechol derivatives having selectin ligand activity |
| 07/02/2008 | EP1937237A1 Novel phloroglucinol derivatives having selectin ligand activity |
| 07/02/2008 | EP1937236A2 Modulation of neurogenesis by hdac inhibition |
| 07/02/2008 | EP1937235A2 Methods for treating viral infections using polyamine analogs |
| 07/02/2008 | EP1937234A1 Use of choline to prevent thrombosis associated with total parenteral nutrition |
| 07/02/2008 | EP1937233A2 Methods of modulating intestinal fluid balance using calciolytics or calcimimetics |
| 07/02/2008 | EP1937232A2 Nutraceutical composition for the treatment of muscle wasting |
| 07/02/2008 | EP1937231A1 Pharmaceutical compositions for the treatment of chronic obstructive pulmonary disease |
| 07/02/2008 | EP1937230A2 M3 muscarinic acetylcholine receptor antagonists |
| 07/02/2008 | EP1937228A1 Pharmaceutical composition based on a morpholinic antimycotic agent and a water-soluble film-forming agent for ungual and periungual application |
| 07/02/2008 | EP1937227A1 Transdermal therapeutic system for administering lipophilic and/or cutaneous low-permeable active substances |
| 07/02/2008 | EP1937226A2 Transdermal galantamine delivery system |
| 07/02/2008 | EP1937224A2 Skincare products |
| 07/02/2008 | EP1937223A1 Sustained-release pellet formulation of alpha1-receptor antagonist and process for the preparation thereof |
| 07/02/2008 | EP1937221A1 Retard formulation for pralnacasan |